FDA
approval
· 2013-02-14
FDA Approved: PRISTIQ EXTENDED-RELEASE — Supplemental Application (Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.)
Summary
The FDA approved a supplemental application to authorize the extended-release formulation of desvenlafaxine succinate (Pristiq Extended-Release) from Wyeth Phar…
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
SUPPL AP for PRISTIQ EXTENDED-RELEASE (DESVENLAFAXINE SUCCINATE)